Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-12, Stock:ABBV, The news for the past five days is as follows:
2018-12-04: NEWS1: AbbVie Falls 3%.NEWS2: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS3: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS4: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS5: IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018.NEWS6: JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial.NEWS7: JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial.NEWS8: AbbVie Stock Could Become a New Happy Pill for Investors.NEWS9: AbbVie Stock Could Become a New Happy Pill for Investors.
2018-12-06: NEWS1: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS2: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS3: AbbVie Falls 3%.NEWS4: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS5: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS6: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS7: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS8: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering.
2018-12-07: NEWS1: A Look at AbbVie’s Earnings Projections for 2018.NEWS2: Assessing AbbVie’s 2018 Revenue Projections.NEWS3: Analysts’ Recommendations for AbbVie in December.NEWS4: AbbVie Falls 4%.NEWS5: [$$] Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices?.
2018-12-10: NEWS1: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS2: Don’t Punish Gilead Stock for Doing Its Job.NEWS3: Don’t Punish Gilead Stock for Doing Its Job.NEWS4: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS5: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS6: Don’t Punish Gilead Stock for Doing Its Job.NEWS7: Humira’s Biosimilar Competition in International Markets.NEWS8: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS9: Considering AbbVie’s 2018 Expense Projections.NEWS10: Exploring AbbVie’s Margin Projections for 2018.
2018-12-11: NEWS1: Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO.NEWS2: Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO.NEWS3: Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO.NEWS4: 7 Stocks Wall Street Is Souring on Right Now.NEWS5: Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800.NEWS6: Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800.NEWS7: 4 “Powell-Proof” Stocks Set to Skyrocket in 2019 (and 1 to Sell Now).NEWS8: 4 “Powell-Proof” Stocks Set to Skyrocket in 2019 (and 1 to Sell Now).NEWS9: Venclexta: A Solid Growth Driver for AbbVie in Future Years.NEWS10: Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800.NEWS11: Imbruvica: A Major Oncology Asset for AbbVie in 2018.NEWS12: How Worried Should You Be About AbbVie's $5.8 Billion Boondoggle?.NEWS13: How Worried Should You Be About AbbVie's $5.8 Billion Boondoggle?.NEWS14: Humira: AbbVie’s Major Revenue Driver in 2018.NEWS15: How Worried Should You Be About AbbVie&apos;s $5.8 Billion Boondoggle?.NEWS16: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS17: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.

Answer: Rise